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Antiviral strategies to inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the
pathogenic consequences of COVID-19 are urgently required. Here we demonstrate that the NRF2 anti-
oxidant gene expression pathway is suppressed in biopsies obtained from COVID-19 patients. Further, we
uncover that NRF2 agonists 4-octyl-itaconate (4-OI) and the clinically approved dimethyl fumarate (DMF)
induce a potent cellular anti-viral program, which potently inhibits replication of SARS-CoV2 across cell
lines. The anti-viral program extended to inhibit the replication of several other pathogenic viruses
including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-
independent mechanism. In addition, induction of NRF2 by 4-OI and DMF limited host in ammatory
responses to SARS-CoV2 infection associated with airway COVID-19 pathology. In conclusion, NRF2
agonists 4-OI and DMF induce a distinct IFN-independent antiviral program that is broadly effective in
limiting virus replication and suppressing the pro-in ammatory responses of human pathogenic viruses,
including SARS-CoV2.
 
One Sentence Summary: NRF2 agonists 4-octyl-itaconate (4-OI) and dimethyl fumarate inhibited SARS-
CoV2 replication and virus-induced in ammatory responses, as well as replication of other human
pathogenic viruses.
Introduction
The 2020 SARS-CoV2 pandemic emphasizes the urgent need to identify cellular factors and pathways
that can be targeted by new broad-spectrum anti-viral therapies. Viral infections usually cause disease in
humans through both direct cytopathogenic effects and through excessive in ammatory responses of
the infected host. This also seems to be the case with SARS-CoV2 as COVID-19 patients develop cytokine
storms that are very likely to contribute to, if not drive, immunopathology and severe disease(1, 2). For
these reasons, anti-viral therapies must aim to not only inhibit viral replication but also to limit
in ammatory responses of the host.
Nuclear factor (erythroid-derived 2) -like 2 (NRF2) functions as a cap´n´collar basic leucine zipper family
of transcription factors characterized structurally by the presence of NRF2-ECH homology domains(3). At
homeostasis, NRF2 is kept inactive in the cytosol by its inhibitor protein KEAP1 (Kelch-like ECH-
associated protein 1), which targets NRF2 for proteasomal degradation(4). In response to oxidative
stress, KEAP1 is inactivated and NRF2 is released to induce NRF2-responsive genes. In general, the genes
under the control of NRF2 protect against stress-induced cell death and NRF2 has thus been suggested
as the master regulator of tissue damage during infection(5). Importantly, NRF2 is now demonstrated as
an important regulator of the in ammatory response(6, 7) and functions as a transcriptional repressor of
in ammatory genes, most notably interleukin (IL-) 1b, in murine macrophages(8). Recent reports have
now demonstrated that NRF2 is induced by several cell derived metabolites including itaconate and
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fumarate, to limit in ammatory responses to stimulation of TLR signaling with lipopolysaccharide
stimulation(9). The chemically synthesized and cell-permeable derivative of itaconate, 4-octyl-itaconate
(4-OI) was then demonstrated to be a very potent NRF2 inducer(9). Of special interest is the derivative of
fumarate, dimethyl fumarate (DMF), a US Food and Drug Administration (FDA) approved drug, which is
used as an anti-in ammatory therapeutic in multiple sclerosis (MS) and demonstrated, at least in animal
models, a potent capacity to suppress pathogenic in ammation through a Nrf2-dependent
mechanism(10, 11).
Besides limiting the in ammatory response to LPS, induction of NRF2 by 4-OI also inhibits the Stimulator
of Interferon Genes (STING) antiviral pathway along with interferon (IFN) stimulated gene expression(12).
In opposition to this anti-viral effect of NRF2 on the IFN-response a recent single-cell RNA-seq analysis
has demonstrated that NRF2 gene expression signatures correlated negatively with susceptibility to HSV1
infection (13). If NRF2 agonists can be used to limit viral replication of SARS-CoV2 or other pathogenic
viruses is, however, not known.
Here we demonstrate that expression of NRF2-dependent genes is suppressed in biopsies from COVID-19
patients and that treatment of cells with NRF2 agonists 4-OI and DMF induces a strong anti-viral program
that limits SARS-CoV2 replication. The anti-viral effect of activating NRF2 extended to other pathogenic
viruses including Herpes Simplex Virus-1 and-2 (HSV-1 and HSV-2), Vaccinia Virus (VACV), and Zika Virus
(ZIKV). Further, 4-OI and DMF limited the release of pro-in ammatory cytokines in response to SARS-
CoV2 infection and to virus-derived ligands through a mechanism that limits IRF3 dimerization. In
summary, we demonstrate that NRF2 agonists are plausible broad-spectrum anti-viral and anti-
in ammatory agents and we suggest a repurposing of the already clinically approved DMF for the
treatment of SARS-CoV2.
Results
NRF2 dependent anti-oxidant response is suppressed in COVID-19 patient biopsies
To identify host factors or pathways that are important for controlling SARS-CoV2 infection, publicly
available transcriptome data sets including transcriptome analysis of lung biopsies from COVID-19
patients were analyzed using differential expression analysis. As shown in Fig. 1a-d, genes linked with
in ammatory and anti-viral pathways, including RIG-I receptor and Toll-like receptor signaling, were highly
enriched in COVID-19 patient samples, whereas genes associated with the NRF2 dependent anti-oxidant
response were highly suppressed. These data indicate that SARS-CoV2 targets the anti-oxidant NRF2
pathway and thus suggests that the NRF2 pathway restricts SARS-CoV2 replication.
 
 
NRF2 agonists 4-OI and dimethyl fumarate are strong inhibitors of SARS-CoV2 replication
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Considering that NRF2 suppresses anti-viral IFN-responses, it was surprising to discover that treatment of
Vero cells with 4-OI generated a peak 5-log reduction in SARS-CoV2 RNA levels in a dose dependent
manner (Fig. 2a+b). Further, subsequent release of progeny SARS-CoV2 virus particles to the cell
supernatant was equally decreased by 4-OI treatment as measured by TCID50 assay and plaque assay
(Fig. 2c-f). The reduced viral replication led to reduced virus-induced cytotoxicity of the infected Vero cells
determined by lactate dehydrogenase release assay and by immunoblotting for cleaved Caspase 3 and
Poly(ADP-Ribose) Polymerase 1 (PARP-1), which are hallmark indicators of apoptosis(14) (Fig, 2g+h).
Interestingly, the observation that Nrf2 pathway is inhibited in response to SARS-CoV-2 infection could be
recapitulated in SARS-CoV-2 infected Vero cells as demonstrated by both the basal decrease in Nrf2-
driven proteins HO-1 and NqO1 and their incapacity to be induced by Nrf2 agonist 4-OI (Fig. 2h). The
effect of 4-OI was also retained in the lung cancer cell line Calu-3, where SARS-CoV2 RNA levels were
reduced by >2-logs (Fig. 2i), while release of progeny virus was reduced by > 6-logs based on TCID50
analysis of cell supernatants (Fig. 2j+k). In the immortalized human epithelial cell line NuLi total infection
levels were relatively low compared to what we could observe in Calu3 and Vero cells but 4-OI treatment
still reduced SARS-CoV2 RNA levels by approximately 50-fold (Fig. 2l+m). We further tested the anti-viral
effect towards SARS-CoV2 in primary human airway epithelial (HAE) cultures (Fig. 2n). Here, 4-OI
treatment also signi cantly reduced viral RNA levels (Fig. 2o). Interestingly, when treating Calu3 cells with
DMF, a known NRF2 inducer and clinically approved drug in the  rst-line-of treatment of multiple
sclerosis, we could observe an anti-viral effect toward SARS-CoV2 replication similar in magnitude as
what we had observed with 4-OI (Fig 2p) as well as a signi cant effect when using Vero cells (Fig. 2q).
These data demonstrate that NRF2 inducers 4-OI and DMF induce potent anti-viral responses that




Activation of NRF2 with 4-OI broadly inhibits viral replication through an IFN-independent pathway
The anti-viral effect of 4-OI was not restricted to SARS-CoV2 but also extended to other human
pathogenic viruses. Using the human keratinocyte cell line HaCaT as a model of Herpes Simplex Virus
(HSV) type 1 and 2 we could observe that treatment with 4-OI reduced both the release of progeny virus,
the cellular content of virus RNA determined by RNA sequence analysis, and viral protein as determined
by both immunoblotting and  ow cytometry (Fig. 3a-e and Fig. S1). By contrast, the expression of NRF2-
inducible genes Heme Oxygenase 1 (HO-1), NAD(P)H dehydrogenase 1 (NqO1), and Sequestosome 1
(SQSTM1) was highly increased in response to 4-OI treatment (Fig. 2c and Fig. S1). The anti-viral effect
of 4-OI was dependent on NRF2 as silencing hereof by siRNA clearly reduced the suppression of HSV1
infection by 4-OI (Fig. 2f-g).
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Vaccinia virus (VACV) belongs to the family of human pathogenic poxviruses. We used HaCaT cells, but
also bone marrow derived dendritic cells (BMDCs), to test if the anti-viral effect of 4-OI extended to these
viruses. Here we could observe that both HaCaT cells and BMDCs became highly resistant to infection
with VACV when these were pre-treated with 4-OI as measured by plaque assay and  ow cytometry (Fig.
2h-l). For both HSV1 and VACV the anti-viral effect of 4-OI was extended to other cell type including
murine cancer cell line 4T1 and human renal carcinoma 786-O cells (Fig. S2). Interestingly, the anti-viral
effect of 4-OI was not extended to infection with vesicular stomatitis virus (VSV) emphasizing that the
anti-viral program induced by 4-OI effectively inhibits replication of many, but not all, viruses (Fig. S2).
The anti-viral effect of 4-OI relied on intracellular restriction of replication, since viral entry was not
affected by 4-OI treatment – if anything it seemed to be slightly increased (Fig. S3).
To determine if the anti-viral effect of 4-OI extended to an in vivo model of viral pathogenesis,  female
C57BL6J mice were treated with 4-OI prior to vaginal inoculation with HSV; pre-treatment with 4-OI
decreased disease progression (Fig. S4), an effect that was enhanced in mice de cient in STING
(TMEM173–/–) most likely to due to the pro-viral effect 4-OI has on the STING signaling pathway(12, 15),
which is eliminated in these mice.
Finally, we tested the e cacy of 4-OI on Zika virus, an important human pathogenic virus causing mild
symptoms in the competent adult but severe disease when transmitted in utero(16). Here, we could
demonstrate that the anti-viral program induced by 4-OI reduced replication of Zika virus in the human
lung cancer cell line A549 and in the human liver cell line Huh-7 (Fig. 2m-n). Given that Vero cells are
de cient in type I IFN(17), this suggested that the inhibitory effect of 4-OI was actually independent of
type I IFN signaling. To address this possibility, we used either HaCaT cells, de cient in Signal Transducer
and Activator of Transcription 1 (STAT1), which is necessary for type I IFN-signaling(18); or de cient in
STING, which is central to type I IFN-response to DNA viruses. Here, cells were treated with 4-OI, followed
by infection with HSV1 and VACV. Replication of both viruses was inhibited by 4-OI in STAT1 KO cells and
for HSV1 also in STING KO cells as measured by plaque assay and expression of viral proteins by
immunoblotting and  ow cytometry (Fig. S5). In conclusion, 4-OI induces an NRF2 mediated anti-viral





4-OI and DMF suppress the in ammatory response to SARS-CoV2
In COVID-19, an uncontrolled pro-in ammatory cytokine storm contributes to disease pathogenesis and
lung damage (19). For this reason, we investigated if 4-OI and DMF could inhibit expression of pro-
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in ammatory cytokines induced by SARS-CoV2. In Calu-3 cells, infection with SARS-CoV2 increased the
expression of IFNB1, C-X-C motif chemokine 10 (CXCL10), Tumor Necrosis Factor alpha (TNFA), IL-1B
and C-C chemokine ligand 5 (CCL5). Interestingly, this was abolished by pretreatment with 4-OI thus
severely reducing the pro-in ammatory response to SARS-CoV2 (Fig. 4a-b). By contrast, expression of the
NRF2 inducible gene HMOX1 was highly increased in response to 4-OI treatment (Fig. 4c). The potential
anti-in ammatory effect of 4-OI in this context was supported when using HAE cultures. Here, treatment
with 4-OI also reduced the expression of IFNB1, CXCL10, TNFa, and CCL5 in the context of SARS-CoV2
infection (Fig. 4d-e), while increasing the expression of the NRF2 inducible gene HMOX1 (Fig. 4f). A
similar pattern was seen in experiments where Calu3 cells were treated with DMF before SARS-CoV2
infection. Here, IFNB1, CXCL10 and CCL5 mRNA levels were highly reduced in DMF treated cells while
TNFA mRNA levels seemed unaffected (Fig. 4g+h). By contrast, treatment with DMF increased the mRNA
expression levels of NRF2 inducible gene HMOX1 (Fig. 4i). As in ammatory responses often stem from
immune cells we also tested the effect of 4-OI on Peripheral Blood Mononuclear Cells (PBMCs) harvested
from healthy donors. Although stimulation of PBMCs with SARS-CoV2 yielded a very weak induction of
CXCL10 compared to sendai virus (SeV) infection, and no detectable induction of other cytokines, 4-OI
treatment also reduced CXCL10 mRNA levels in this context (Fig. 4j). Further, when using PBMCs
harvested from four individual patients with severe COVID-19 and admitted to hospital Intensive Care
Units (ICUs), we could conclude that in three out of four patients, expression levels of CXCL10 were
increased when compared to healthy controls; and that in all four patients, these levels were strongly
reduced to or below normal when treating the PBMCs with 4-OI (Fig. 4k) indicating that 4-OI is able to
relieve in ammatory responses induced by SARS-CoV2 in PBMCs in vivo.
The observed decrease in anti-viral and pro-in ammatory responses could possibly be explained by the 4-
OI mediated reduction in cellular viral RNA with subsequent reduced induction of cytokines through
cellular RNA sensors such as RIG-I. We therefore investigated the effect of 4-OI on the induction of IFN
and of IFN stimulated genes (ISGs) responses activated by a sequence optimized RIG-I agonist M8(20).
Interestingly, 4-OI treatment reduced IFN-responses induced by this RIG-I agonist M8 (Fig 4l-m), through
an effect linked to the inhibition of Interferon Regulatory Factor 3 (IRF3) dimerization but not of upstream
phosphorylation of Tank Binding Kinase 1 (TBK1) or of IRF3 expression itself (Fig 4n). Importantly, NRF2
expression itself was closely associated with the inhibition of IRF3 dimerization and host antiviral gene
expression, since NRF2 silencing by siRNA was su cient to restore IRF3 dimerization and limit the
inhibitory effect of 4-OI (Fig. 4n-o). When using the constitutively active form of IRF3, IRF3(5D) (21), 4-OI
was still able to block IRF3 dimerization, and again, this effect was eliminated when NRF2 expression
was suppressed by siRNA (Fig 4p-q). These data indicate that an NRF2 inducible and dependent
mechanism targets the induction of IFN by inhibition of IRF3 dimerization. This phenomenon is likely to
add to the inhibition of SARS-CoV2 induced cytokine release we could observe when using NRF2
agonists. We have previously reported that 4-OI inhibits the expression of STING, which is important for
the induction of the IFN-response in cells stimulated with cytosolic DNA(12). In line, 4-OI inhibited the IFN-
response to HSV1 infection and to stimulation with STING agonists dsDNA and cGAMP (Fig. 4R-T).
Page 9/26
Discussion
Altogether, this study demonstrated that the expression of NRF2 dependent anti-oxidant genes was
signi cantly inhibited in COVID-19 patients, and that the NRF2 agonists 4-OI and DMF inhibited both
SARS-CoV2 replication, as well as the expression of associated in ammatory markers. The ability of
these NRF2 inducers to also reduce potentially pathogenic IFN- and in ammatory responses while
retaining their anti-viral properties is unique to these compounds and promotes their applicability to
prevent virus-induced pathology. As DMF is currently used as an anti-in ammatory drug in relapsing-
remitting MS, this drug could be easily repurposed and tested in clinical trials to test of its ability to limit
SARS-CoV2 replication and in ammation-induced pathology in COVID-19 patients. Our observation that
4-OI strongly inhibits the IFN-response to both cytosolic DNA and d RNA, which are canonical anti-viral
pathways, but still retain its ability to block viral replication also suggests a spectrum of unidenti ed
cellular programs that are inducible through NRF2 and e ciently restrict viral replication independently of
IFNs. This is supported by already mentioned negative correlation between expression of NRF2-inducible
genes and infection with HSV1 discovered by Wyler et al., through single cell transcriptome analysis.
Similarly to how IFNs block viral replication through the induction of hundreds of effector IFN-stimulated
effector genes, the NRF2 controlled anti-viral program might also consists of a myriad of mechanisms
that restrict viral replication each by targeting distinct stages of viral replication.
Future studies will determine if patients developing severe SARS-CoV2 pathology also have an underlying
NRF2 de ciency, leading to reduced control of viral replication, coupled with excess in ammatory
responses.  Further, it could be valuable to investigate if patients already in DMF therapy have altered
susceptibility to SARS-CoV2 infection and if those infected have milder symptoms and reduced cytokine
load. Finally, the fact that 4-OI effectively limited replication of several human pathogenic viruses
demonstrated that 4-OI, or related chemically modi ed compounds such as DMF, could be evaluated as
broad-spectrum anti-viral agents for protection against seasonal and pandemic viral infections in general.
Declarations
 
Funding: This research work was supported by Ester M og Konrad Kristian Sigurdssons Dyreværnsfond,
Beckett-Fonden, Kong Christian IX og Dronning Louises Jubilæumslegat, Læge Sofus Carl Emil Friis og
Hustru Olga Doris Friis´ legat, Købmand I Odense Johan og Hanne Weimann Født Seedorffs Legat, UK
Medical Research Council (MRC core funding of the MRC Human Immunology Unit; JR), Lundbeck
foundation (R303-2018-3379 and R219-2016-878, and R268-2016-3927), and Independent Research Fund
Denmark – Medical Sciences (9039-00078B, 4004-00047B, and 0214-00001B). CarlsbergFoundation
(Semper Ardens) and European Research Council (ERC-AdG ENVISION; 786602). Marie Skłodowska-Curie
Action of the European Commission # 813343 and Italian Cancer Research Society  #22891 to JH.
Author contributions: DO and CH conceived the project and prepared  gures. DO, ALH, JT, JC, BH, MI, AK,
LR, MI, MS, SF, MT, ML, HH, VG, AH, AK, CG, CM, LB, AT, TA, JH, RO, and AA performed experiments,
Page 10/26
analyzed data, and prepared  gures. EF performed bioinformatics and prepared  gures. TM was
responsible for including COVID-19 patients and achieving patient material.  TA, JR, AA, TM, SP, and CH
planned experiments and analyzed data. CH drafted and  nalized the manuscript. JH planned
experiments and edited the manuscript. EF and ML performed bioinformatics and prepared  gures.  MJ
facilitated SARS-CoV2 laboratories. Authors declare no competing interests. Data and materials




1. P. Mehta et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395,
1033-1034 (2020).
2. C. Huang et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet 395, 497-506 (2020).
3. G. P. Sykiotis, D. Bohmann, Stress-activated cap'n'collar transcription factors in aging and human
disease. Science signaling 3, re3 (2010).
4. J. D. Hayes, A. T. Dinkova-Kostova, The Nrf2 regulatory network provides an interface between redox
and intermediary metabolism. Trends Biochem Sci 39, 199-218 (2014).
5. M. P. Soares, A. M. Ribeiro, Nrf2 as a master regulator of tissue damage control and disease
tolerance to infection. Biochem Soc Trans 43, 663-668 (2015).
6. R. K. Thimmulappa et al., Nrf2 is a critical regulator of the innate immune response and survival
during experimental sepsis. J. Clin. Invest. 116, 984-995 (2006).
7. R. K. Thimmulappa et al., Nrf2-dependent protection from LPS induced in ammatory response and
mortality by CDDO-Imidazolide. Biochem. Biophys. Res. Commun. 351, 883-889 (2006).
8. E. H. Kobayashi et al., Nrf2 suppresses macrophage in ammatory response by blocking
proin ammatory cytokine transcription. Nature communications 7, 11624 (2016).
9. E. L. Mills et al., Itaconate is an anti-in ammatory metabolite that activates Nrf2 via alkylation of
KEAP1. Nature 556, 113-117 (2018).
10. R. Gold, R. A. Linker, M. Stangel, Fumaric acid and its esters: an emerging treatment for multiple
sclerosis with antioxidative mechanism of action. Clin. Immunol. 142, 44-48 (2012).
11. R. A. Linker et al., Fumaric acid esters exert neuroprotective effects in neuroin ammation via
activation of the Nrf2 antioxidant pathway. Brain 134, 678-692 (2011).
12. D. Olagnier et al., Nrf2 negatively regulates STING indicating a link between antiviral sensing and
metabolic reprogramming. Nature communications 9, 3506 (2018).
13. E. Wyler et al., Single-cell RNA-sequencing of herpes simplex virus 1-infected cells connects NRF2
activation to an antiviral program. Nature communications 10, 4878 (2019).
Page 11/26
14. G. V. Chaitanya, A. J. Steven, P. P. Babu, PARP-1 cleavage fragments: signatures of cell-death
proteases in neurodegeneration. Cell Commun Signal 8, 31 (2010).
15. C. Gunderstofte et al., Nrf2 Negatively Regulates Type I Interferon Responses and Increases
Susceptibility to Herpes Genital Infection in Mice. Front Immunol 10, 2101 (2019).
16. A. Fajardo, J. Cristina, P. Moreno, Emergence and Spreading Potential of Zika Virus. Front Microbiol 7,
1667 (2016).
17. J. Desmyter, J. L. Melnick, W. E. Rawls, Defectiveness of interferon production and of rubella virus
interference in a line of African green monkey kidney cells (Vero). J. Virol. 2, 955-961 (1968).
18. L. B. Ivashkiv, L. T. Donlin, Regulation of type I interferon responses. Nat Rev Immunol 14, 36-49
(2014).
19. S. Davidson, S. Crotta, T. M. McCabe, A. Wack, Pathogenic potential of interferon alphabeta in acute
in uenza infection. Nature communications 5, 3864 (2014).
20. L. Castiello et al., An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell
death markers in human cancer cells and dendritic cell activation. Cancer Immunol. Immunother. 68,
1479-1492 (2019).
21. R. Lin, Y. Mamane, J. Hiscott, Structural and functional analysis of interferon regulatory factor 3:
localization of the transactivation and autoinhibitory domains. Mol. Cell. Biol. 19, 2465-2474 (1999).
Material And Methods
Cell lines, reagents and culture conditions
Human lung adenocarcinoma epithelial A549 cells, immortalized human HaCaT keratinocytes, Calu-3
epithelial lung cancer cells and human embryonic kidney HEK293T cells were kindly provided by Søren R.
Paludan (Aarhus University, Denmark) and cultured in DMEM (Lonza) supplemented with 10% heat
inactivated fetal calf serum, 200 IU.mL-1 penicillin, 100 mg.mL-1 streptomycin and 600 mg.mL-1 glutamine
(hereafter termed DMEM complete). Vero E6 cells expressing hTMPRSS2 were a kind gift of Makoto
Takeda (University of Tokyo, Japan)(1) and were cultured in DMEM (Lonza) supplemented with 10% heat
inactivated fetal calf serum, 200 IU.mL-1 penicillin, 100 mg.mL-1 streptomycin, 600 mg.mL-1 glutamine
and 10 mg.mL-1 blasticidin. All cell lines were regularly tested for mycoplasma contamination by
sequencing from GATC Biotech (Germany). 4-octyl-itaconate (4-OI) was chemically synthetized by
Thomas B. Poulsen (Aarhus University, Denmark) and was dissolved in DMSO as previously described
here(2).
 
To obtain bone marrow-derived cells (BMDCs), a cell suspension from femurs of C57BL/6 mice (Charles
River) was cultured for 6-8 days at 37ºC in RPMI-1640 medium supplemented with 3% FBS and 10% of
J558 cell line supernatant containing GM-CSF. Cells were seeded at a density of 106 cells/ml and medium
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was partially replaced every 2 days. BSC-1 cells (ECACC) were maintained in DMEM supplemented with
5% FBS,  
2 mM glutamine, 200 IU/ml penicillin and 100 IU/ml streptomycin at 37ºC 5% CO2.
 
For generation of KO cell line clones in HaCaT cells speci c guide RNA sequences targeting STING (5’-
AGAGCACACTCTCCGGTACC-3’) or STAT1 (5’-TTAATGATGAACTAGTGGAG-3’) were cloned into the
plasmids pX461 (Addgene) (STING) or LentiCRISPR v2 (Addgene) (STAT1). Wildtype HaCaT cells were
transfected with the plasmids using the Lipofectamine 2000 Reagent (Invitrogen, Life Tecnologies). 72 h
post transfection, the GFP expressing cells were sorted as single cells by FACS and clones were grown to
larger cultures (STING). Or 24 h post transfection, the cells were seeded in a dilution su cient to obtain
single cells clones after the puromycin selection. The 2 μg mL-1 puromycin selection was initiated 48 h
post transfection and continued for 72 h (STAT1). Hereafter, single cell clones were grown to larger
cultures which were validated for absence of protein by western blotting and functional analysis to
con rm the biological effect of the gene de ciency.
 
Viruses
We used the SARS-CoV2 strain #291.3 FR-4286  isolated from a patient in Germany, and kindly donated
by professor Georg Kochs (Freiburg). The virus was propagated in Vero-TMPRSS2 cells(3). Validation
and SARS-CoV2 genome detection was performed with Taqman based qPCR using SARS-CoV2 speci c
primers and probes with the following sequences: Forward primer: AAATTTTGGGGACCAGGAAC, reverse
primer: TGGCACCTGTGTAGGTCAAC, Probe: FAM-ATGTCGCGCATTGGCATGGA-BHQ. HSV-1 KOS strain
expressing GFP (HSV-1–GFP), HSV-2 333 strain and HSV-2 MS strain were kindly provided by Søren R.
Paludan (Aarhus University, Aarhus, Denmark). All HSVs were propagated in Vero cells, puri ed by ultra-
centrifugation, and titrated by standard plaque assay as previously described (4). HaCat cells were
infected with the different HSVs at a multiplicity of infection (MOI) of 0.01 in a small volume of serum-
free medium for 1 h at 37°C. Prior to analysis, cells were incubated with DMEM complete for an
additional day of culture. VACV Western reserve strain (VACV-WR) was a recombinant vaccinia
virus (VACV) named vtag2GFP expressing the tag2GFP under the control of strong synthetic VACV
early/late promoter was kindly provided by Dr.  Rafael Blasco (INIA, Spain). VACV-WR and
vtag2GFP stocks were semi-puri ed by centrifugation through a 36% sucrose cushion and titrated twice
by plaque assay. The Brazilian ZIKV isolate ZIKV/H.sapiens/Brazil/PE243/2015 was originally described
in (5) and was grown on Vero cells. Viral titers were determined by plaque assay on A549 BVDV NPro
cells (kind gift from R. Randall, St Andrews). These cells are optimized for virus growth as they stably




Quanti cation of HSV-1 entry in the presence of 4-OI was performed using the cold binding assay
previously described(7). Cells were pretreated with 4-OI (150 µM) or DMSO (control) for 48 hours. Cells
were pre-incubated at 4oC for 30 minutes, then incubated with HSV-1 at a MOI of 10 for 1 hours at 4oC.
Cells were then shifted to 37oC for 1 hours to activate virus internalization. After that, cells were washed
twice with PBS, then uninternalized virus particles were washed with citric acid buffer (135 mM NaCl, 10
mM KCl, 40 mM citric acid, pH 3) incubation for 5 minutes, then cells were washed twice more with PBS.
Cells were scraped and genomic DNA was extracted using QIAamp DNA mini kit (QIAGEN). Quantitative
PCR were performed using UL30-F and UL30-R primers for HSV-1 genomic DNA. Primer sequence: UL30-




Primary cells and culture conditions
Peripheral Blood Mononuclear cells (PBMCs) were isolated from healthy donors (blood donors gave
written consent as accordingly to the ethical guidelines at Aarhus University Hospital) by Ficoll Paque
gradient centrifugation (GE Healthcare). Monocytes were separated using a monocyte enrichment kit
(STEMCELL) according to the manufacturer’s instructions or from PBMCs by adherence to plastic in
RPMI 1640 supplemented with 10% AB-positive human serum. Differentiation of monocytes to
macrophages was achieved by culturing in Dulbecco’s Modi ed Eagle Medium (DMEM) supplemented
with 10% heat inactivated AB-positive human serum 9 days in the presence of 10 ng/ml M-CSF (R&D
Systems), as previously reported in (8). 
 
Patients included in this study
All patients were positive for SARS-CoV2 by PCR from throat swab and admitted to the ICU and receiving
ventilatory support due to severe pneumonia with a component of acute respiratory distress syndrome
(ARDS). P1 27-years old male, day 14 at in ICU. P2 57-year-old female, day 9 in ICU. P3 43 years-old male,
day 5 in ICU.  P4 28 years-old female, day 3 in ICU.
 
Air-Liquid Interface Epithelium model
Primary nasal cells were isolated using a nasal brush (Dent-O-Care, #620B) inserted into the nasal
turbinations and twisted. Cells were isolated from the brush by gently expelling monolayer medium
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(Airway Epithelial Cells Basal Medium, PromoCell, #C-21260 + 1 pack of Airway Epithelial Cell Growth
Medium Supplement, PromoCell, #39160 + 100 U/ml Penicillin/Streptomycin, Gibco #10378) and PBS to
wash of cells. Cells were cultured in monolayer culture in tissue culture  ask (Sarstedt, TC: Standart
#83.3911) coated with 0,1 mg/ml Bovine type I collagen solution (Sigma-Aldrich, #804592, diluted in
sterile ddH2O). Monolayer cultures were split using 1x Trypsin mixed with 0.3 mM EDTA (10x Trypsin (2,5
%), Gibco, #15090, diluted to working concentration in PBS + UltraPure 0.5 M EDTA, Invitrogen, #15575)
at approx. 80% con uency. At passage two, cells were seeded at 2-3x10^4 cells on 6,5 mm Transwell
membranes (Corning, #3470) coated with 30 ug/ml Bovine type I collagen solution (Sigma-Aldrich,
#804592, diluted in sterile ddH2O). Cells were seeded and submerged in 2x P/S (200 U/ml Pen/Strep)
DMEM-low glycose (Sigma-Aldrich, D5921) mixed one to one with 2x Monolayer medium (Airway
Epithelium Cell Basal Medium, (PromoCell, #C-21260) supplemented with 2 packs of Airway Epithelial
Cell Growth Medium Supplement (PromoCell, #C-39160) without triiodothyronine + 1 ml of 1.5 mg/ml
BSA). When cultures reach full con uency ALI (=Air-liquid interface) is introduced and medium is
changed to ALI medium (Pneumacult ALI medium kit (StemCell, #5001) with ALI medium supplement
(StemCell, #5001) and 100 U/ml Pen/strep) supplemented with 24 ug of hydrocortisone (StemCell,
#07925) and 0.2 mg heparin (StemCell, #07980). Membranes was allowed at least 21 days of
differentiation veri ed by extensive cilia beating and mucus covering.
Upon initiation of treatment ALI cultures was washed for 5 minutes using DMEM (low glycose, no
additives) and baso-lateral medium changed for ALI medium containing either 150 uM 4-OI or DMSO.
Baso-lateral medium containing treatment was left overnight. 100 ul of DMEM (low glycose) with 150 uM
or DMSO was additionally added to the apical compartment overnight. At time of infection, apical
medium was removed and 100 ul DMEM (low glycose) containing SARS-CoV-2 at MOI 0.1 was added to
all membranes for 1 hour and placed in 37 oC incubator. After 1-hour apical infection medium was
removed and membranes placed in 37 oC incubator for 24 hours before harvest.
At time of harvest, baso-lateral medium was removed and 500 ul Trypsin/EDTA was added bao-laterally
and 200 ul was added apically. After approx. 5 minutes cells were harvested using 5% FPB/DMEM (low
glycose). Cells were lysed for RNA isolation using lysisbuffer from High Pure RNA Isolation Kit (Roche
Diagnostics, #11828665001). For Western blot cells were lysed in RIPA buffer containing 1/10 Protease
inhibitor (Roche), 1/1000 Benzonase (Sigma, #E1014) and 1/50 0.5 M Sodium Flouride.
 
Short-interfering RNA (siRNA)-mediated knock down
For short interfering RNA experiments, HaCat cells were transfected in 6-well plates with 80 pmol of
human Nrf2(1) (sc-37030) or control si RNA (sc-37007) diluted in serum and antibiotic free DMEM and
using Lipofectamine RNAi Max as per manufacturer’s instructions. HaCat cells were incubated for 72h in
the presence of the siRNA before being processed.
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dsDNA, cGAMP and optimized RIG-I agonist stimulation of cells.
HSV-60 naked, a viral dsDNA motif, 2’3’-cGAMP, a STING ligand, and M8, a sequence optimized RIG-I
agonist (9) were obtained from Invivogen and John Hiscott (Pasteur Institute, Rome), respectively.
Intracellular delivery of dsDNA and cGAMP was achieved using Lipofectamine 2000 (Invitrogen) diluted
in serum-free medium with a ratio of Lipo.dsDNA/cGAMP of 1:1. Final concentration for both dsDNA and
cGAMP was 4mg.mL-1. Intracellular delivery of M8 was achieved using Lipofectamine RNAiMax




BMDCs, HaCaT and HaCaT Stat1 KO were incubated or not with 150 µM 4-OI for 48 h before infection
with vtag2GFP using 0.1 or 0.01 pfu/cell at 37 ºC for 60 min. Then, infected cells were washed to remove
potential unbound viruses and infection proceeded at 37 ºC.
To determine the proportion of vtag2GFP infected cells GFP expression was detected at 16 hpi by  ow
cytometry using triplicates. Brie y, cells were harvested, washed with FACS buffer (PBS, 0.01%
sodium azide, and 0.1% BSA) and  xed with paraformaldehyde 4% in PBS for 10 min. After extensive
washing with FACS buffer, 2x104 cells were scored  
and analyzed in a FACSCalibur  ow cytometer (BD Sciences) per experimental condition in triplicates. To
determine VACV virus titres, HaCaT and HaCaT STAT1 KO cells were previously stimulated for 48 h or not
with 150 µM 4-OI and then infected with VACV-WR using 0.1 or 0.01 pfu/cell at 37 ºC. At 24 hpi, cells were
harvested in their own media, centrifuged at 1,800 × g for 5 min, and resuspended in 0.5 ml of fresh
medium. In all cases, samples were frozen, thawed three times and titrated using duplicates in BSC-1
cells. Brie y, precon uent monolayers of BSC-1 cells were infected with 10-fold serial dilutions of viral
inoculums for 1h at 37ºC. Then, inoculum was replaced with semi-solid carboxy-methyl cellulose (Sigma)
media with 2 % FBS and cells  xed in 10 % formaldehyde at 3 dpi. Plaques were stained with 0.1% (w/v)
crystal-violet. Two independent experiments were performed.
 
Zika Virus infections.
A549 cells (kind gift from G. Kochs, Freiburg) and Huh-7 were cultured at 37°C in Dulbecco’s Modi ed
Eagle Medium (DMEM), supplemented with 10% FCS and 2mM L-Glutamine. Cells were seeded in 24 well
plates and pre-treated with 4-octyl-itaconate (4-OI) (150uM) for 48h. Cells were infected with ZIKV (moi
0.1) for 1h. 4-OI was freshly added when the medium was changed.Cells were lysed and total RNA was
extracted at 96hpi using the QIAshredder (Qiagen) and RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. RNA was reverse transcribed using SuperScript II Reverse Transcriptase
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(Invitrogen) into cDNA that was then used for qPCR with SYBR green PCR kit (Life Technologies). CT
values were normalized to GAPDH (ΔCT). SYBR green primer probes used include GAPDH (for:




The assay was performed as follows. 2 x 104 Vero E6 TMPRSS2 cells were seeded in 90ul DMEM (Gibco,
+ 2% FCS (Sigma-aldrich) + 1% Pen/Strep (Gibco) + L-Glutamine (Sigma-Aldrich) per well in  at-bottom
96-well plates. 24h after, samples were titrated onto the cells by addition of 10ul of a 10-fold serial
dilution. One full plate was used per sample analyzed. Each dilution of supernatant were represented 8
times on a plate. The cells were incubated for 72h in a humidi ed CO2 incubator at 37 ˚C, 5% CO2, before
 xing with 5% Formalin (Sigma-Aldrich) and staining with crystal violet solution (Sigma-Aldrich). Images
were taken using a Leica DMi1, microscope with a Leica MC170 HD camera. TCDI50 % virus titer
calculated by Reed-Muench method.
 
Western blot.
HaCat cells were lysed in 100 mL of ice-cold Pierce RIPA lysis buffer (Thermo Scienti c) supplemented
with 10 mM NaF, 1x complete protease cocktail inhibitor (Roche) and 5 IU.mL-1 benzonaze (Sigma),
respectively. Protein concentration was determined using a BCA protein assay kit (Thermo Scienti c).
Whole-cell lysates were denatured for 3 min at 95°C in presence of 1x XT Sample Buffer (BioRad) and 1x
XT reducing agent (BioRad). 10-40 mg of reduced samples was separated by SDS-PAGE on 4-20%
Criterion TGX precast gradient gels (BioRad). Each gel was run initially for 15 min at 70V and 45 min at
120V. Transfer onto PVDF membranes (BioRad) was done using a Trans-Blot Turbo Transfer system for 7
min. Membranes were blocked for 1h with 5% skim-milk (Sigma Aldrich) at room temperature in PBS
supplemented with 0.05% Tween-20 (PBST). Membranes were fractionated in smaller pieces and probed
overnight at 4°C with any of the following speci c primary antibodies in PBST: anti-Nrf2 (12721, Cell
Signaling 1:1000), anti-TBK1/NAK (3013, Cell Signaling 1:1000), anti-phospho-TBK1/NAK (5483, Cell
Signaling 1:1000), anti-SQSTM1/p62 (8025, Cell Signaling 1:1000), anti-IRF3 (11904, Cell Signaling
1:1000), anti-phospho-IRF3 (4947, Cell Signaling 1:500), anti-HO-1 (5853, Cell Signaling 1:1000), anti-
IFIT1 (14769, Cell Signaling 1:1000), anti-NRF2 (12721, Cell Signaling 1:1000), anti-STING (13647, Cell
Signaling 1:1000), anti-NqO1 (3187, Cell Signaling 1:1000), and anti-Vinculin (18799, Cell Signaling
1:1000) used as loading control. After three washes in PBST, secondary antibodies, peroxidase-
conjugated F(ab)2 donkey anti-mouse IgG (H+L) (1:10000) or peroxidase-conjugated F(ab)2 donkey anti-
rabbit IgG (H+L) (1:10000) (Jackson ImmunoResearch) were added to the membrane in PBST 1% milk for
1h at room temperature. All membranes were washed three times and exposed using either the
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SuperSignal West Pico PLUS chemiluminescent substrate or the SuperSignal West Femto maximum
sensitivity substrate (ThermoScienti c) and an Image Quant LAS4000 mini imager (GE Healthcare).
 
Semi-native WB Dimerization assay.
IRF3 dimerization was assayed under semi-native conditions. Cells were lysed in ice-cold Pierce RIPA lysis
buffer (Thermo Scienti c) supplemented with 10 mM NaF, 1x complete protease cocktail inhibitor
(Roche) and 5 IU/mL benzonaze (Sigma). Protein concentration was determined using a BCA protein
assay kit (Thermo Scienti c). Whole-cell lysates were mixed with 1x XT Sample Buffer (BioRad); samples
were neither reduced nor heated before separation was done on 4-20% Criterion TGX precast gradient gels
(BioRad) by SDS-PAGE electrophoresis. Each gel was run initially for 15 min at 70V and 15 min at 120V.
Transfer onto PVDF membranes (BioRad) was done using a Trans-Blot Turbo Transfer system for 7 min.
Membranes were blocked for 1h with 5% skim-milk (Sigma Aldrich) at room temperature in PBS
supplemented with 0.05% Tween-20 (PBST). Membranes were probed overnight at 4°C with the following
speci c primary antibody in PBST: anti-IRF3. After three washes in PBST, secondary antibodies,
peroxidase-conjugated F(ab)2 donkey anti-rabbit IgG (H+L) (1:10000) (Jackson Immuno Research) were
added to the membrane in PBST 1% milk for 1h at room temperature. All membranes were washed three
times and exposed using either the SuperSignal West Pico PLUS chemiluminescent substrate or the
SuperSignal West Femto maximum sensitivity substrate (Thermo Scienti c).
 
qPCR analysis.
Gene expression was determined by real-time quantitative PCR, using TaqMan detection systems
(Applied Biosciences). RNA was extracted using the High Pure RNA Isolation kit (Roche) and RNA quality
was assessed by Nanodrop spectrometry (Thermo Fisher). RNA levels were analyzed using premade





COVID19 data set analysis (Fig. 1): RNA-seq data was obtained from an already available dataset from
Blanco-Melo (doi: https://doi.org/10.1101/2020.03.24.004655). From the raw read-counts differential
expression values were calculated using DESeq2(10). Signi cantly differentially expressed genes
(SDEGs) were selected based on the thresholds of adjusted P-value <0.05 and absolute fold change of 2
(Fig. 1A). In order to focus on commonality across the different conditions with respect to generating
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clinically relevant hypotheses, the 815 SDEGs obtained from the biopsy sample were checked if these
were also present in the list of SDEGs in the other conditions. All genes that occur in at least 3 or more
other conditions were included in the  nal list, resulting in 113 genes. Finally, the expression values for all
genes in the  nal list across all conditions were assembled, clustered using Euclidean distance metric
and Ward’s variance minimization algorithm, and visualized as a heatmap using Python3.7 and seaborn
cluster-map tools. Then the gene-sets from each of the outlined clusters were used for pathway
enrichment analysis using Enrichr (Fig. 1B) (11). Finally, the STRING database(12) was used to construct
the cloud network starting from lists of genes manually annotated for NRF2, in ammation and IFN
signaling. Edges and nodes were extracted from STRING and imported to Cytoscape (13) version 3.7 for
further visualization (Fig. 1D).
 
 
Transcriptome analysis of HSV1-infected HaCaT cells
RNA sequencing was performed in collaboration with BGI Europe Genome Center (Copenhagen,
Denmark) following the standard operational procedure as described before(14). Brie y, the quality of
total RNA was checked using the Agilent 2100 bioanalyzer. To construct the sequencing library for
MGIseq-2000, approximately 1 μg of polyA enriched RNA was used for library construction using the
MGIEasy RNA Directional Library Prep Kit (MGI Tech). Next, paired-end sequencing with 100 cycles was
performed using the MGISEQ-2000 sequencing instrument, according to the manufacturer’s instructions.
We generated an average of 63 million raw reads for each sample. The clean RNA reads were  rst aligned
to the hg19 UCSC RefSeq (RNA sequences, GRCh37) using bowtie2 at  rst. To map the transcripts from
the viruses, the unmapped reads were then aligned to the coding sequence of the human herpesvirus 1
(KOS strain). The expression of human genes and virus genes were performed by transforming mapped
transcript reads to TPM using RSEM(15). The normalized expression were estimated and normalized by
DEseq2. Differentially expressed genes were de ned as genes with fold change over two-folds and




RNA sequencing  les generated for analysis of HaCaT cells infected with HSV in the presence or absence
of 4-OI have been deposited to the data depository database (CNGBdb, https://db.cngb.org) with the




The project was approved by Institutional review boards at Aarhus University Hospital, by the Danish
National Committee in Health Research Ethics (1-10-72-80-20) and the Danish Data protection Agency in
accordance with the ethical standards of the Helsinki Declaration. Written informed consent was
obtained from all study participants.
 
Statistical analysis.
Values were expressed as the means ± SEM. Graphs and statistics were computed using Graph Pad
Prism 7. An unpaired, two-tailed Student's t-test was used to determine signi cance of the difference
between the control and each experimental condition. P values of less than 0.05 were considered
statistically signi cant, ***, p<0.001; **, p<0.01, and *, p<0.05.
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Expression of NRF2-driven genes is suppressed in COVID-19 patient biopsies (a) Bar-chart of the number
of transcripts that show differential expression (up and down). Genes with p<0.05 and Log2 fold change
in COVID-19 patient lung biopsies were normalized against healthy lung biopsies, and in cell lines Calu3,
NHBE and A549 infected with either SARS-CoV2, In uenza A virus (IAV), Respiratory Syncytial virus (RSV),
or human parain uenza virus type 3 (HPIV3) were normalized against mock treated cells. (b) Heat map of
the subset of genes signi cantly differentially expressed in COVID-19 biopsies and simultaneously
differentially expressed in at least 3 of the other conditions tested. The genes in each cluster was used for
pathway enrichment analysis. Genes in cluster 1 are dominantly down regulated in COVID-19 biopsies.
The genes in cluster 2 and 3 are up-regulated in biopsies and in most other test-samples. (c) heat map of
NRF2 driven genes deferentially expressed in COVID-19 and in other conditions. (d) Cloud analysis of
NRF2-driven differentially expressed genes. Subsets annotated as in ammation/NF B signaling and Type
I IFN signaling exhibit different expression patterns. The experiment is a re-analysis of data from Blanco-
Melo et al., https://doi.org/10.1101/2020.03.24.004655.
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Figure 2
4-Octyl-itaconate (4-OI) and dimethyl fumarate (DMF) inhibit SARS-CoV2 replication (a-e) Vero E6
expressing human TMPRSS2 cells were treated with 4-OI (125 M) or lower concentrations were indicated
for 48h and subsequently infected with SARS-CoV-2 at a MOI of 0.1 or 0.5 for 48h, respectively. Infection
and replication were assessed by qPCR and TCID50 or plaque assay, respectively. Graphs in (a+b+e)
display means and s.e.m. of one experiment performed in duplicates. (f) Supernatants from (e) were also
assessed for viral titers by semi-solid agarose plaque assay. From (a-f) A two-tailed Student’s t-test was
used to determine statistical signi cance where **p< 0.01. (g) Vero E6 expressing human TMPRSS2 cells
were treated with 4-OI (125 M) for 48h and subsequently infected with SARS-CoV-2 at a MOI of 0.1 48h.
Cell death was evaluated using an LDH release assay. Data are the means and s.e.m. of one experiment
performed in sextuplicate where **p< 0.01 has been determined by a two-tailed Student’s t-test. (h) Whole
cell extracts from (g) were immunoblotted for various Nrf2 and death associated markers (i-k) Calu3 cells
were treated with 4-OI (100 M) for 48h and subsequently infected with SARS-CoV-2 (MOI 0.5) for 48h.
Viral RNA content and progeny virus were assessed by qPCR and TCID50, respectively. Data are the
means and s.e.m. of one experiment performed in triplicate where **p< 0.01 has been determined by a
two-tailed Student’s t-test. (l-m) NuLi cells were treated with 4-OI (100 M) for 48h and subsequently
infected with SARS-CoV-2 (MOI 0.5) for 48h. Viral titers were determined by TCID50. Data are the means
and s.e.m. of one experiment performed in duplicate where **p< 0.01 has been determined by a two-tailed
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Student’s t-test. (n) schematic of an HAE culture. (o) HAE cultures (n=4) were treated with 4-OI (125 M)
overnight and were subsequently infected with SARS-CoV-2 (MOI 0.1). Viral genome content was
assessed by qPCR (mean +/- s.e.m. from 4 independent primary HAE cultures). (p-q) Calu-3 cells and Vero
E6 expressing hTMPRSS2 cells were treated with dimethyl fumarate (DMF) (200 M) for 48h and
subsequently infected with SARS-CoV-2 at a MOI of 0.5 and 0.1, respectively. Data are the means and




4-OI broadly inhibits other pathogenic viruses including HSV, VACV, and Zika Virus (a) HaCaT cells treated
with 4-OI (125 M) for 48h and infected with HSV1-GFP (MOI 0.01). Viral titers were determined by plaque
assay. Data are representative of one experiment performed in duplicates where **p< 0.01 has been
determined by a two-tailed Student’s t-test. (b) RNA analyzed using RNA-sequencing (n=3). (c-e) HaCaT
cells treated with 4-OI (125 M) and infected with HSV1-GFP (MOI 0.01). Lysates were analyzed by
immunoblotting with Vinculin (VCL) as loading control and by  ow cytometry (n=7 from three
independent experiments, mean +/- s.e.m.). (f-g) HaCaT cells were lipofected with siRNA for 72h,
subsequently challenged with 4-OI (125 M) before HSV1-GFP infection (MOI 0.01) for 24h. Infectivity and
silencing e ciency was determined by immunoblotting (f) and  ow-cytometry (g). (h-l) HaCaT cells (h-j)
and BMDCs (k-l) were treated with 4-OI (125 M) for 48h and infected with VACV for 24h. Viral titers and
infectivity were determined by plaque assay (h) and  ow cytometry (i-l). (m-n) A549 and Huh-7 cells were
pre-treated with 4-OI for 48h (150 M) and infected with Zika virus (ZIKV) (MOI 0.1) for 4 days. Viral
genome was determined by qPCR. Data are representative on one experiment performed in duplicates
where means and s.e.m are displayed and **p< 0.01 has been determined by a two-tailed Student’s t-test.
Page 25/26
Figure 4
4-OI and DMF limit SARS-CoV2 and HSV induced in ammatory responses. (a-c) Calu-3 treated with 4-OI
(125µM) for 48h before infection with SARS-CoV2 (MOI 0.5) for 48 hours. RNA was extracted for analysis
by qPCR. (d-f) HAE cultures (n=4) were treated overnight with 4-OI at 125µM before SARS-CoV2 infection
(MOI 0.1) for 24 and analysis by qPCR. (g-i) Calu-3 treated with DMF (200 µM) for 48h before infection
with SARS-CoV2 (MOI 0.5) for 48 hours. RNA was extracted for analysis by qPCR. In (a+b+c+g+h+i) data
are representative of one experiment performed in duplicates where means and s.e.m. are displayed. In
(d-f) data are representative of four independent primary HAE cultures where means and s.e.m. are
displayed. (j) Healthy PBMCs were pre-treated overnight with 4-OI (100µM) before a challenge with SARS-
CoV-2 (MOI 10) or sendai virus (SeV) (50 HAU) for an additional 24h. CXCL10 mRNA levels were
determined by qPCR. Data are representative of one healthy donor in triplicate. Experiment has been
performed on two independent healthy donors. (k) PBMCs from four COVID-19 patients (k) and 2 healthy
controls (HC) treated with 4-OI at 100µM overnight before analysis by qPCR. (l-m) HaCaT cells were
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treated with 4-OI (125µM) before stimulation with the sequence optimized RIG-I agonist M8 (10ng/mL)
for 6 hours followed by qPCR gene expression analysis. Data represent the means and s.e.m. of one
experiment performed in triplicate. (n) HaCaT cells were lipofected with indicated siRNAs for 72h before
treatment with M8 (10 ng/mL) for 3 hours followed by analysis by immunoblotting. (o) HaCaT cells were
lipofected with indicated siRNAs for 72h before treatment with 4-OI (125 M) for 48h and stimulation with
M8 (10 ng/mL) for 3 hours followed by analysis by immunoblotting. (p-q) HEK293(p) and HaCaT(q) cells
were transfected with indicated plasmids before treatment with 4-OI at 125µM. In (q), HaCaT cells were
lipofected with siRNAs for 72h before plasmid transfection. Cells were then collected for analysis by
qPCR (p) and immunoblotting (q). (r-t) HaCaT cells were treated with 4-OI at 125µM before infection with
HSV1 at MOI 0.01 or transfection with dsDNA (4 g.mL-1). Cell pellets were collected for qPCR and
immunoblotting at 6 and 3 hours respectively.
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